Exactus (OTCMKTS:EXDI) and Cronos Group (OTCMKTS:CRON) Head to Head Contrast

Exactus (OTCMKTS:EXDI) and Cronos Group (NASDAQ:CRON) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, analyst recommendations and risk.

Institutional & Insider Ownership

12.1% of Cronos Group shares are held by institutional investors. 23.6% of Exactus shares are held by insiders. Comparatively, 7.9% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and target prices for Exactus and Cronos Group, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Exactus 0 0 0 0 N/A
Cronos Group 1 4 4 0 2.33

Cronos Group has a consensus target price of $9.83, indicating a potential upside of 82.44%. Given Cronos Group’s higher probable upside, analysts clearly believe Cronos Group is more favorable than Exactus.

Profitability

This table compares Exactus and Cronos Group’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Exactus -749.90% -349.47% -130.69%
Cronos Group 1,729.07% -2.57% -2.17%

Earnings & Valuation

This table compares Exactus and Cronos Group’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Exactus $350,000.00 10.56 -$9.69 million N/A N/A
Cronos Group $25.64 million 73.55 $1.17 billion $0.67 8.04

Cronos Group has higher revenue and earnings than Exactus.

Volatility & Risk

Exactus has a beta of 5.34, meaning that its stock price is 434% more volatile than the S&P 500. Comparatively, Cronos Group has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500.

Summary

Cronos Group beats Exactus on 10 of the 12 factors compared between the two stocks.

About Exactus

Exactus, Inc., is a farmer and manufacturer of hemp-derived phytocannabinoid products. The company sells its CBD products through its Green Goddess brand and third-party resellers. Exactus is engaged in producing industrial hemp from farms in Oregon and plans to extract and manufacture directly through cGMP facilities. Industrial hemp is a type of cannabis, defined by the federal government as having THC (tetrahydrocannabinol) content of 0.3 percent or less. THC is the psychoactive compound found in cannabis.

About Cronos Group

Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations “MMPR”. The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in Toronto, Canada.

Receive News & Ratings for Exactus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactus and related companies with MarketBeat.com's FREE daily email newsletter.